<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931892</url>
  </required_header>
  <id_info>
    <org_study_id>2007P000280</org_study_id>
    <secondary_id>K23DK082619</secondary_id>
    <nct_id>NCT00931892</nct_id>
  </id_info>
  <brief_title>Serum Markers in Gluten Challenge</brief_title>
  <official_title>Circulating Markers of Celiac Disease Activity During Gluten Challenge - a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The purpose of this research study is to evaluate non-invasive markers of celiac disease&#xD;
           activity in subjects that are on a gluten-free diet, in remission from celiac disease&#xD;
           who undergo gluten challenge.&#xD;
&#xD;
        2. The secondary aims of this protocol are to identify novel mediators important in the&#xD;
           pathophysiology of celiac disease and to evaluate changes in metabolism with gluten&#xD;
           exposure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis of celiac disease carries with it important ramifications. Celiac disease is a&#xD;
      systemic immunologic disorder in which the sentinel lesion is an enteropathy triggered by&#xD;
      polypeptides derived primarily from the gliadin proteins found in wheat, rye and barley.&#xD;
      Ingestion of the offending proteins leads to inflammation and intestinal mucosal damage,&#xD;
      which results in a spectrum of abdominal symptoms, increased intestinal permeability,&#xD;
      malabsorption, occult gastrointestinal bleeding and diarrhea. Systemic manifestations of&#xD;
      celiac disease include a myriad of conditions including malignancy and autoimmune disease.&#xD;
&#xD;
      The only accepted treatment for celiac disease is lifelong adherence to a gluten free diet.&#xD;
      Adherence to this diet, simply put avoiding all foods containing even small amounts of wheat,&#xD;
      rye and barley, has been shown to lead to improvement in the majority of related problems and&#xD;
      normalization of all standard diagnostic tests. Because of this many individuals who present&#xD;
      for evaluation of possible celiac disease but who are already on a gluten free diet cannot be&#xD;
      tested accurately as there is currently no way of differentiating between healthy individuals&#xD;
      and individuals with well treated celiac disease. The standard practice in such cases is to&#xD;
      perform a 'Gluten Challenge' whereby the patient eats the equivalent of 2 slices of bread per&#xD;
      day for six to eight weeks before returning for evaluation with serologic testing and&#xD;
      endoscopy with duodenal biopsy. The use of the gluten challenge in clinical practice is&#xD;
      limited by patient symptoms and resistance to such a long test period, after which it may&#xD;
      take a number of weeks for the intestine to heal and the symptoms to resolve. Autoantibodies&#xD;
      to tissue transglutaminase or antibodies to deamidated gliadin, while being excellent tools&#xD;
      to predict celiac disease in patients who have been on a long-term gluten containing diet,&#xD;
      display low sensitivities to detect short-term and/or recent gluten exposure. For this&#xD;
      reason, it would be very useful if novel circulating markers could be identified that&#xD;
      indicate the presence of celiac disease and in particular would provide an early and less&#xD;
      invasive marker of a positive response to gluten challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crypt Depth to Villous Height Ratio</measure>
    <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
    <description>Histological evaluation of duodenal biopsy samples to evaluate crypt depth to villous height ratio. On the best oriented section of each biopsy fragment, villous height to crypt depth (Vh:Cd) ratio was determined by measuring the mean height /mean depth of adjacent villi/proliferative crypt zones at magnification 100x. Evaluations were considered discrepant Vh:Cd differed by more than 0.5. Overall, there was excellent concordance with the evaluations of the 165 biopsy fragments determined to be optimal for evaluation.&#xD;
The Vh:Cd ratios on individual biopsies from a single averaged to produce a representative Vh:Cd ratio for each endoscopy. Normal Vh:Cd ratio was regarded as 3:1 or greater.&#xD;
Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of Intraepithelial Lymphocytes Per 100 Enterocytes in Duodenal Biopsy Samples</measure>
    <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
    <description>On the best oriented section of each biopsy fragment , the number of intraepithelial lymphocytes (IEL count) per 100 enterocytes was recorded at magnification 400x. IEL counts were considered discrepant if a difference of &gt;10 IELs existed between counts. Overall, there was excellent concordance with the evaluations of the 165 biopsy fragments determined to be optimal for evaluation.&#xD;
The IEL counts on individual biopsies from a single endoscopy were averaged to produce a representative IEL count for each endoscopy.&#xD;
Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Intestinal Permeability (Urinary Lactulose to Mannitol Ratio)</measure>
    <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
    <description>LAMA evaluation has been reported to be an accurate measure of small intestinal mucosal permeability though assessment of differential absorption of lactulose and mannitol. For LAMA testing, a solution containing 7.5 g lactulose and 2 g mannitol in 100 mL of water was ingested by the participants in the evening after visit 1 and in the evening before each other study visit. The participants were asked to fast for at least 4 h and to void completely before drinking the sugar solution, then fast overnight and collect all overnight and morning urine. Urine sample analyzed for lactulose and mannitol using standardized methodology by liquid chromatography-tandem mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Immune Activation</measure>
    <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
    <description>IgA anti-human tissue transglutaminase assay (Inova Diagnostics, Inc., San Diego, USA): negative &lt;20, borderline 20-30, positive &gt;30.&#xD;
IgA/IgG anti- DGP assay : NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Protein Expression in Intestinal Biopsies</measure>
    <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
    <description>Proportion of participants responding to a gluten challenge. Tissue transglutaminase (tTG) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30. Deamidated gliadin peptide (DGP) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Response to Gluten Exposure Determined by Celiac Symptom Index Questionnaire</measure>
    <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
    <description>CSI (Celiac Symptom Index) scores range from 7-80. Higher scores indicate greater degree of symptoms&#xD;
CSI:&#xD;
Leffler DA, Dennis M, Edwards George J, Jamma S, Cook EF, Schuppan D, Kelly CP. A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol. 2009;7:1328-34. PubMed PMID: 19665584.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Protein Expression in Intestinal Biopsies Using Marsh Scores</measure>
    <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
    <description>Proportion of participants responding to a gluten challenge. Tissue transglutaminase (tTG) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30. Deamidated gliadin peptide (DGP) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Response to Gluten Exposure Determined by Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
    <description>Measure Description: GSRS (Gastrointestinal Symptom Rating Scale) scores range 15-105 with higher scores indicating greater degree of symptoms&#xD;
GSRS:&#xD;
Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129-134. doi:10.1007/BF01535722</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Low gluten group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will eat 3g of gluten per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High gluten group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will eat 10g of gluten per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gluten</intervention_name>
    <description>3g</description>
    <arm_group_label>Low gluten group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gluten</intervention_name>
    <description>10g</description>
    <arm_group_label>High gluten group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 17 and 72 years, inclusive.&#xD;
&#xD;
          2. Subject must have been diagnosed with celiac disease by duodenal / jejunal biopsy at&#xD;
             least 6 months prior to entrance into the study.&#xD;
&#xD;
          3. Subject has Anti-Tissue Transglutaminase (anti-tTG) ≤ 20 EU as measured by serology.&#xD;
&#xD;
          4. Subject must be on a gluten-free diet for at least the past 6 months.&#xD;
&#xD;
          5. Female subjects should be either post-menopausal (amenorrhea for at least 24&#xD;
             consecutive months), surgically sterile, or women of child-bearing potential (WOCP)&#xD;
             with a negative urine beta human chorionic gonadotropin (HCG) pregnancy test prior to&#xD;
             entering the study and who are using or agree to use acceptable methods of&#xD;
             contraception. Abstinence is an acceptable means of avoiding pregnancy as long as the&#xD;
             subject agrees to use contraception if they become sexually active. Acceptable&#xD;
             contraceptives include intrauterine devices (IUDs), hormonal contraceptives (oral,&#xD;
             depo, patch or injectable) in use for one month prior to screening and double barrier&#xD;
             methods such as condoms or diaphragms with spermicidal gel or foam.&#xD;
&#xD;
          6. Subject must sign an Institutional Review Board approved informed consent and agree to&#xD;
             complete required clinic visits.&#xD;
&#xD;
          7. BMI between 18.5 and 38, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has Anti-Tissue Transglutaminase (anti-tTG) &gt; 20 EU as measured by serology.&#xD;
&#xD;
          2. Subject has other food intolerances or food allergies (other than celiac disease) that&#xD;
             would interfere with the conduct of the study).&#xD;
&#xD;
          3. Subject has a history of severe acute symptomatic reactions to sporadic gluten&#xD;
             ingestion&#xD;
&#xD;
          4. Subject has any chronic active GI disease other than celiac disease (e.g. Crohn's&#xD;
             disease, IBS).&#xD;
&#xD;
          5. Subjects with symptomatic neurological or psychiatric disease(s) that would interfere&#xD;
             with the conduct of the study.&#xD;
&#xD;
          6. Subject has clinically significant abnormal laboratory test results at the screening&#xD;
             visit or as determined by the Principal Investigator&#xD;
&#xD;
          7. Subject is pregnant or breast feeding.&#xD;
&#xD;
          8. Subject (premenopausal females) is sexually active without contraception.&#xD;
&#xD;
          9. Subject should not have been on steroids in the past 3 months.&#xD;
&#xD;
         10. Subject is deemed inappropriate by the Principal Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciaran P Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel A Leffler, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bidmc.org/CentersandDepartments/Departments/DigestiveDiseaseCenter/CeliacDiseaseCenter/ResearchStudies.aspx</url>
    <description>BIDMC Celiac Center Research website</description>
  </link>
  <reference>
    <citation>Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988 Feb;33(2):129-34.</citation>
    <PMID>3123181</PMID>
  </reference>
  <results_reference>
    <citation>Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review.</citation>
    <PMID>29460921</PMID>
  </results_reference>
  <results_reference>
    <citation>Leffler DA, Dennis M, Edwards George J, Jamma S, Cook EF, Schuppan D, Kelly CP. A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol. 2009 Dec;7(12):1328-34, 1334.e1-3. doi: 10.1016/j.cgh.2009.07.031. Epub 2009 Aug 7.</citation>
    <PMID>19665584</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <results_first_submitted>February 21, 2020</results_first_submitted>
  <results_first_submitted_qc>May 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2021</results_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Ciaran Kelly</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>celiac disease</keyword>
  <keyword>gluten challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>21 patients were enrolled in the study. 1 patient was found to be negative for DQ2 and DQ8, therefore did not have Celiac disease. This patient was excluded from the study. Therefore, for the study we had a total of 20 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Gluten Group</title>
          <description>Subjects will eat 3g of gluten per day&#xD;
Gluten: 3g</description>
        </group>
        <group group_id="P2">
          <title>High Gluten Group</title>
          <description>Subjects will eat 10g of gluten per day&#xD;
Gluten: 10g</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Completed Gluten Challenge</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Completed Endoscopies</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Endoscopy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Endoscopy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Third Endoscopy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient did not complete third endoscopy due to discomfort</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects with biopsy proven coelic dieasese in remission were enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Low Gluten Group</title>
          <description>Participants meeting inclusion criteria were randomized into the low gluten group. These participants ate two slices of wheat bread per day (3 g of gluten). Bread was procured from a standard source and gluten dose tested using the RIDASCREEN Gliadin R5 antibody ELISA. The study included a 14-day run-in period followed by a 14 day gluten challenge and a final visit 14 days post-gluten challenge. Other than the dispensed bread, subjects were instructed to remain on their gluten-free diet throughout the duration of the study.&#xD;
Gluten: 3g</description>
        </group>
        <group group_id="B2">
          <title>High Gluten Group</title>
          <description>Participants meeting inclusion criteria were randomized into the low gluten group. These participants ate five slices of wheat bread per day (10 g of gluten). Bread was procured from a standard source and gluten dose tested using the RIDASCREEN Gliadin R5 antibody ELISA. The study included a 14-day run-in period followed by a 14 day gluten challenge and a final visit 14 days post-gluten challenge. Other than the dispensed bread, subjects were instructed to remain on their gluten-free diet throughout the duration of the study.&#xD;
Gluten: 10g</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="13.0"/>
                    <measurement group_id="B2" value="38.8" spread="13.1"/>
                    <measurement group_id="B3" value="43.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Celiac Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="13.9"/>
                    <measurement group_id="B2" value="31.0" spread="11.7"/>
                    <measurement group_id="B3" value="35.7" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months since Celiac Disease diagnosis</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="21.3"/>
                    <measurement group_id="B2" value="92.5" spread="49.1"/>
                    <measurement group_id="B3" value="62.3" spread="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Laboratory Characteristics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HLA DQ2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HLA DQ8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HLA DQ2 + DQ 8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HLA A1 * 05 alone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Villous height to crypt depth ratio</title>
          <description>Villous height to crypt depth (Vh: Cd) ratio was determined by measuring the mean height/mean depth of adjacent villi/proliferative crypt zones at magnification 100x&#xD;
Vh:Cd and IEL count Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.05" spread="0.80"/>
                    <measurement group_id="B2" value="4.33" spread="6.69"/>
                    <measurement group_id="B3" value="2.21" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of Intraepithelial lymphocytes</title>
          <description>Villous lymphocyte infiltration was recorded at magnification 300 x as number of intraepithelial lymphocytes (IEL count) per 100 enterocytes&#xD;
Vh:Cd and IEL count Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.10" spread="13.66"/>
                    <measurement group_id="B2" value="28.4" spread="13.3"/>
                    <measurement group_id="B3" value="32.59" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline tissue transglutaminase (tTG)</title>
          <description>NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.76" spread="8.30"/>
                    <measurement group_id="B2" value="8.27" spread="5.70"/>
                    <measurement group_id="B3" value="11.00" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Deamidated gliadin peptide (DGP)</title>
          <description>NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.70" spread="2.59"/>
                    <measurement group_id="B2" value="14.04" spread="26.49"/>
                    <measurement group_id="B3" value="10.90" spread="19.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Celiac Dietary Adherence test (CDAT)</title>
          <description>CDAT scores range from 7-35 for scores. Lower scores indicate better dietary adherence</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.33" spread="3.2"/>
                    <measurement group_id="B2" value="11.40" spread="2.9"/>
                    <measurement group_id="B3" value="11.37" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Celiac Symptom Index (CSI)</title>
          <description>CSI (Celiac Symptom Index) scores range from 7-80. Higher scores indicate greater degree of symptoms&#xD;
CSI:&#xD;
Leffler DA, Dennis M, Edwards George J, Jamma S, Cook EF, Schuppan D, Kelly CP. A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol. 2009;7:1328-34. PubMed PMID: 19665584.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.50" spread="5.78"/>
                    <measurement group_id="B2" value="22.50" spread="4.99"/>
                    <measurement group_id="B3" value="25.26" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Gastrointestinal Symptom Rating Scale (GSRS)</title>
          <description>GSRS (Gastrointestinal Symptom Rating Scale) scores range 15-105 with higher scores indicating greater degree of symptoms&#xD;
GSRS:&#xD;
Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129-134. doi:10.1007/BF01535722</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.88" spread="9.58"/>
                    <measurement group_id="B2" value="19.20" spread="3.26"/>
                    <measurement group_id="B3" value="20.32" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Quality of Life Visual Analog Scale (VAS)</title>
          <description>VAS (Quality of Life Visual Analog Scale) scores range from 0-100 with higher scores indicating better health related quality of life</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.00" spread="13.10"/>
                    <measurement group_id="B2" value="84.40" spread="12.10"/>
                    <measurement group_id="B3" value="82.20" spread="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Crypt Depth to Villous Height Ratio</title>
        <description>Histological evaluation of duodenal biopsy samples to evaluate crypt depth to villous height ratio. On the best oriented section of each biopsy fragment, villous height to crypt depth (Vh:Cd) ratio was determined by measuring the mean height /mean depth of adjacent villi/proliferative crypt zones at magnification 100x. Evaluations were considered discrepant Vh:Cd differed by more than 0.5. Overall, there was excellent concordance with the evaluations of the 165 biopsy fragments determined to be optimal for evaluation.&#xD;
The Vh:Cd ratios on individual biopsies from a single averaged to produce a representative Vh:Cd ratio for each endoscopy. Normal Vh:Cd ratio was regarded as 3:1 or greater.&#xD;
Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
        <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
        <population>Subjects with biopsy proven celiac disease in remission were enrolled. For Day 3, 17 subjects had evaluable pathology biopsies. On Day 14, 19 participants had evaluable pathology biopsies.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline (Day -14) Low Gluten Group</title>
            <description>Villous height to crypt depth ratio in low gluten group&#xD;
In the low gluten group, subjects consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O2">
            <title>Baseline (Day -14) High Gluten Group</title>
            <description>Villous height to crypt depth ratio in high gluten group&#xD;
In the high gluten group, subjects consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O3">
            <title>Day 3 Low Gluten Group</title>
            <description>Villous height to crypt depth ratio in low gluten group&#xD;
In the low gluten group, subjects consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O4">
            <title>Day 3 High Gluten Group</title>
            <description>Villous height to crypt depth ratio in high gluten group&#xD;
In the high gluten group, subjects consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O5">
            <title>Day 14 Low Gluten Group</title>
            <description>Villous height to crypt depth ratio in low gluten group&#xD;
In the low gluten group, subjects consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O6">
            <title>Day 14 High Gluten Group</title>
            <description>Villous height to crypt depth ratio in high gluten group.&#xD;
In the high gluten group subjects consume 10 grams of gluten per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Crypt Depth to Villous Height Ratio</title>
          <description>Histological evaluation of duodenal biopsy samples to evaluate crypt depth to villous height ratio. On the best oriented section of each biopsy fragment, villous height to crypt depth (Vh:Cd) ratio was determined by measuring the mean height /mean depth of adjacent villi/proliferative crypt zones at magnification 100x. Evaluations were considered discrepant Vh:Cd differed by more than 0.5. Overall, there was excellent concordance with the evaluations of the 165 biopsy fragments determined to be optimal for evaluation.&#xD;
The Vh:Cd ratios on individual biopsies from a single averaged to produce a representative Vh:Cd ratio for each endoscopy. Normal Vh:Cd ratio was regarded as 3:1 or greater.&#xD;
Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
          <population>Subjects with biopsy proven celiac disease in remission were enrolled. For Day 3, 17 subjects had evaluable pathology biopsies. On Day 14, 19 participants had evaluable pathology biopsies.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.80"/>
                    <measurement group_id="O2" value="4.33" spread="6.69"/>
                    <measurement group_id="O3" value="1.19" spread="0.67"/>
                    <measurement group_id="O4" value="2.02" spread="0.99"/>
                    <measurement group_id="O5" value="0.98" spread="0.85"/>
                    <measurement group_id="O6" value="1.26" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Intraepithelial Lymphocytes Per 100 Enterocytes in Duodenal Biopsy Samples</title>
        <description>On the best oriented section of each biopsy fragment , the number of intraepithelial lymphocytes (IEL count) per 100 enterocytes was recorded at magnification 400x. IEL counts were considered discrepant if a difference of &gt;10 IELs existed between counts. Overall, there was excellent concordance with the evaluations of the 165 biopsy fragments determined to be optimal for evaluation.&#xD;
The IEL counts on individual biopsies from a single endoscopy were averaged to produce a representative IEL count for each endoscopy.&#xD;
Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
        <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
        <population>Subjects with biopsy proven celiac disease in remission were enrolled. For Day 3, 17 subjects had evaluable pathology biopsies. On Day 14, 19 participants had evaluable pathology biopsies.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline (Day -14) Low Gluten Dose Group</title>
            <description>Intraepithelial lymphocyte count(per 100 enterocytes) in low gluten dose groups.&#xD;
Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O2">
            <title>Baseline (Day -14) High Gluten Dose Group</title>
            <description>Intraepithelial lymphocyte count(per 100 enterocytes) in high gluten dose groups.&#xD;
Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O3">
            <title>Day 3 Low Gluten Dose Group</title>
            <description>Intraepithelial lymphocyte count(per 100 enterocytes) in low gluten dose groups.&#xD;
Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O4">
            <title>Day 3 High Gluten Dose Group</title>
            <description>Intraepithelial lymphocyte count(per 100 enterocytes) in high gluten dose groups.&#xD;
Subjects in the low gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O5">
            <title>Day 14 Low Gluten Dose Group</title>
            <description>Intraepithelial lymphocyte count(per 100 enterocytes) in low gluten dose groups.&#xD;
Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O6">
            <title>Day 14 High Gluten Dose Group</title>
            <description>Intraepithelial lymphocyte count(per 100 enterocytes) in high gluten dose groups.&#xD;
Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Intraepithelial Lymphocytes Per 100 Enterocytes in Duodenal Biopsy Samples</title>
          <description>On the best oriented section of each biopsy fragment , the number of intraepithelial lymphocytes (IEL count) per 100 enterocytes was recorded at magnification 400x. IEL counts were considered discrepant if a difference of &gt;10 IELs existed between counts. Overall, there was excellent concordance with the evaluations of the 165 biopsy fragments determined to be optimal for evaluation.&#xD;
The IEL counts on individual biopsies from a single endoscopy were averaged to produce a representative IEL count for each endoscopy.&#xD;
Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review. PubMed PMID: 29460921.</description>
          <population>Subjects with biopsy proven celiac disease in remission were enrolled. For Day 3, 17 subjects had evaluable pathology biopsies. On Day 14, 19 participants had evaluable pathology biopsies.</population>
          <units>Count of Lymphocytes Per 100 Enterocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.08" spread="13.66"/>
                    <measurement group_id="O2" value="28.91" spread="15.81"/>
                    <measurement group_id="O3" value="44.89" spread="20.49"/>
                    <measurement group_id="O4" value="30.68" spread="18.09"/>
                    <measurement group_id="O5" value="47.95" spread="14.30"/>
                    <measurement group_id="O6" value="52.36" spread="28.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Intestinal Permeability (Urinary Lactulose to Mannitol Ratio)</title>
        <description>LAMA evaluation has been reported to be an accurate measure of small intestinal mucosal permeability though assessment of differential absorption of lactulose and mannitol. For LAMA testing, a solution containing 7.5 g lactulose and 2 g mannitol in 100 mL of water was ingested by the participants in the evening after visit 1 and in the evening before each other study visit. The participants were asked to fast for at least 4 h and to void completely before drinking the sugar solution, then fast overnight and collect all overnight and morning urine. Urine sample analyzed for lactulose and mannitol using standardized methodology by liquid chromatography-tandem mass spectrometry.</description>
        <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
        <population>Subjects with biopsy proven celiac disease in remission were enrolled. Measures of intestinal permeability (urinary lactulose to mannitol ratio) (LAMA) . Four participants were unable to tolerate LAMA testing due to gastrointestinal symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Day -14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O2">
            <title>Day -14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O3">
            <title>Day 0 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O4">
            <title>Day 0 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O5">
            <title>Day 3 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O6">
            <title>Day 3 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O7">
            <title>Day 7 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O8">
            <title>Day 7 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O9">
            <title>Day 14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O10">
            <title>Day 14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O11">
            <title>Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O12">
            <title>Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Intestinal Permeability (Urinary Lactulose to Mannitol Ratio)</title>
          <description>LAMA evaluation has been reported to be an accurate measure of small intestinal mucosal permeability though assessment of differential absorption of lactulose and mannitol. For LAMA testing, a solution containing 7.5 g lactulose and 2 g mannitol in 100 mL of water was ingested by the participants in the evening after visit 1 and in the evening before each other study visit. The participants were asked to fast for at least 4 h and to void completely before drinking the sugar solution, then fast overnight and collect all overnight and morning urine. Urine sample analyzed for lactulose and mannitol using standardized methodology by liquid chromatography-tandem mass spectrometry.</description>
          <population>Subjects with biopsy proven celiac disease in remission were enrolled. Measures of intestinal permeability (urinary lactulose to mannitol ratio) (LAMA) . Four participants were unable to tolerate LAMA testing due to gastrointestinal symptoms.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.17"/>
                    <measurement group_id="O2" value="0.24" spread="0.25"/>
                    <measurement group_id="O3" value="0.65" spread="1.15"/>
                    <measurement group_id="O4" value="0.17" spread="0.15"/>
                    <measurement group_id="O5" value="0.25" spread="0.15"/>
                    <measurement group_id="O6" value="0.44" spread="0.60"/>
                    <measurement group_id="O7" value="0.45" spread="0.71"/>
                    <measurement group_id="O8" value="0.29" spread="0.28"/>
                    <measurement group_id="O9" value="0.89" spread="1.53"/>
                    <measurement group_id="O10" value="0.59" spread="0.52"/>
                    <measurement group_id="O11" value="0.29" spread="0.24"/>
                    <measurement group_id="O12" value="0.57" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.387</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Immune Activation</title>
        <description>IgA anti-human tissue transglutaminase assay (Inova Diagnostics, Inc., San Diego, USA): negative &lt;20, borderline 20-30, positive &gt;30.&#xD;
IgA/IgG anti- DGP assay : NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
        <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
        <population>Subjects with biopsy proven celiac disease in remission were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Day -14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O2">
            <title>Day -14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O3">
            <title>Day 0 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O4">
            <title>Day 0 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O5">
            <title>Day 3 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O6">
            <title>Day 3 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O7">
            <title>Day 7 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O8">
            <title>Day 7 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O9">
            <title>Day 14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O10">
            <title>Day 14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O11">
            <title>Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O12">
            <title>Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Immune Activation</title>
          <description>IgA anti-human tissue transglutaminase assay (Inova Diagnostics, Inc., San Diego, USA): negative &lt;20, borderline 20-30, positive &gt;30.&#xD;
IgA/IgG anti- DGP assay : NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
          <population>Subjects with biopsy proven celiac disease in remission were enrolled.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA anti-tTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.70" spread="2.60"/>
                    <measurement group_id="O2" value="10.34" spread="5.75"/>
                    <measurement group_id="O3" value="13.76" spread="10.88"/>
                    <measurement group_id="O4" value="11.50" spread="6.63"/>
                    <measurement group_id="O5" value="11.84" spread="9.50"/>
                    <measurement group_id="O6" value="10.34" spread="5.75"/>
                    <measurement group_id="O7" value="13.77" spread="10.90"/>
                    <measurement group_id="O8" value="11.50" spread="6.63"/>
                    <measurement group_id="O9" value="12.63" spread="8.73"/>
                    <measurement group_id="O10" value="15.16" spread="10.30"/>
                    <measurement group_id="O11" value="37.81" spread="45.07"/>
                    <measurement group_id="O12" value="43.20" spread="53.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA/IgG anti- DGP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.70" spread="2.60"/>
                    <measurement group_id="O2" value="14.04" spread="26.49"/>
                    <measurement group_id="O3" value="7.83" spread="2.54"/>
                    <measurement group_id="O4" value="14.69" spread="27.01"/>
                    <measurement group_id="O5" value="12.95" spread="8.26"/>
                    <measurement group_id="O6" value="14.04" spread="26.49"/>
                    <measurement group_id="O7" value="7.83" spread="2.54"/>
                    <measurement group_id="O8" value="14.69" spread="27.01"/>
                    <measurement group_id="O9" value="17.81" spread="22.97"/>
                    <measurement group_id="O10" value="22.74" spread="29.31"/>
                    <measurement group_id="O11" value="45.42" spread="62.56"/>
                    <measurement group_id="O12" value="41.95" spread="33.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>P Value for IgA anti-tTG</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>P Value for IgA/IgG anti-DGP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>P Value for IgA anti-tTG</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>P Value for IgA/IgG anti-DGP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Protein Expression in Intestinal Biopsies</title>
        <description>Proportion of participants responding to a gluten challenge. Tissue transglutaminase (tTG) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30. Deamidated gliadin peptide (DGP) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
        <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
        <population>All 20 subjects were included for the tTG and DGP analysis. For Day 28 High Gluten Challenge Dose Group, 1 participant had both a tTG and DGP &gt;20 which is why the count is greater than the number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O2">
            <title>Day 14 High Gluten Challenge Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O3">
            <title>Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O4">
            <title>Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O5">
            <title>Day 14 or Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O6">
            <title>Day 14 or Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Protein Expression in Intestinal Biopsies</title>
          <description>Proportion of participants responding to a gluten challenge. Tissue transglutaminase (tTG) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30. Deamidated gliadin peptide (DGP) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
          <population>All 20 subjects were included for the tTG and DGP analysis. For Day 28 High Gluten Challenge Dose Group, 1 participant had both a tTG and DGP &gt;20 which is why the count is greater than the number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tTG &gt; 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DGP &gt; 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tTG &gt; 20 or DGP &gt; 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Response to Gluten Exposure Determined by Celiac Symptom Index Questionnaire</title>
        <description>CSI (Celiac Symptom Index) scores range from 7-80. Higher scores indicate greater degree of symptoms&#xD;
CSI:&#xD;
Leffler DA, Dennis M, Edwards George J, Jamma S, Cook EF, Schuppan D, Kelly CP. A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol. 2009;7:1328-34. PubMed PMID: 19665584.</description>
        <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
        <population>Subjects with biopsy proven celiac disease in remission were enrolled. On Day -14, one subject in the high gluten dose group missed the CSI. On Day 7 one subject in the high gluten dose group missed the CSI. On Day 14 one subject in the high gluten dose group missed the CSI. On Day 28, one subject in the high gluten dose group and one subject in the low gluten dose missed the CSI.</population>
        <group_list>
          <group group_id="O1">
            <title>Day -14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O2">
            <title>Day -14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O3">
            <title>Day 0 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O4">
            <title>Day 0 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O5">
            <title>Day 3 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O6">
            <title>Day 3 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O7">
            <title>Day 7 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O8">
            <title>Day 7 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O9">
            <title>Day 14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O10">
            <title>Day 14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O11">
            <title>Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O12">
            <title>Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Response to Gluten Exposure Determined by Celiac Symptom Index Questionnaire</title>
          <description>CSI (Celiac Symptom Index) scores range from 7-80. Higher scores indicate greater degree of symptoms&#xD;
CSI:&#xD;
Leffler DA, Dennis M, Edwards George J, Jamma S, Cook EF, Schuppan D, Kelly CP. A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol. 2009;7:1328-34. PubMed PMID: 19665584.</description>
          <population>Subjects with biopsy proven celiac disease in remission were enrolled. On Day -14, one subject in the high gluten dose group missed the CSI. On Day 7 one subject in the high gluten dose group missed the CSI. On Day 14 one subject in the high gluten dose group missed the CSI. On Day 28, one subject in the high gluten dose group and one subject in the low gluten dose missed the CSI.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="5.78"/>
                    <measurement group_id="O2" value="22.5" spread="4.99"/>
                    <measurement group_id="O3" value="28.44" spread="6.44"/>
                    <measurement group_id="O4" value="23.00" spread="5.29"/>
                    <measurement group_id="O5" value="30.33" spread="7.81"/>
                    <measurement group_id="O6" value="27.54" spread="10.27"/>
                    <measurement group_id="O7" value="31.11" spread="7.90"/>
                    <measurement group_id="O8" value="28.80" spread="13.36"/>
                    <measurement group_id="O9" value="31.38" spread="11.40"/>
                    <measurement group_id="O10" value="31.00" spread="12.70"/>
                    <measurement group_id="O11" value="26.88" spread="7.70"/>
                    <measurement group_id="O12" value="23.90" spread="6.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>P Value for Celiac Symptom Index (CSI) score for Day 3 of Gluten Challenge</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>P Value for Celiac Symptom Index (CSI) Score from baseline to Day 14</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>P Value for Celiac Symptom Index (CSI)score between high gluten group and low gluten group across study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Protein Expression in Intestinal Biopsies Using Marsh Scores</title>
        <description>Proportion of participants responding to a gluten challenge. Tissue transglutaminase (tTG) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30. Deamidated gliadin peptide (DGP) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
        <time_frame>Screening (Day -7 to -14), Day 3, Day 14</time_frame>
        <population>Only 19 subjects were evaluated for Marsh scores because one patient had a single endoscopy which did not produce evaluable samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O2">
            <title>Day 14 High Gluten Challenge Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O3">
            <title>Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O4">
            <title>Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
          <group group_id="O5">
            <title>Day 14 or Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day</description>
          </group>
          <group group_id="O6">
            <title>Day 14 or Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Protein Expression in Intestinal Biopsies Using Marsh Scores</title>
          <description>Proportion of participants responding to a gluten challenge. Tissue transglutaminase (tTG) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30. Deamidated gliadin peptide (DGP) scoring: NEGATIVE &lt;20, BORDERLINE 20-30, POSITIVE &gt;30 METHOD IS INOVA ANTI-DEAMIDATED GLIADIN PEPTIDE IGA/IGG.</description>
          <population>Only 19 subjects were evaluated for Marsh scores because one patient had a single endoscopy which did not produce evaluable samples.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Marsh III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marsh III or tTG &gt;20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marsh III or DGP &gt; 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marsh III or DGP &gt; 20 or tTG &gt; 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Response to Gluten Exposure Determined by Gastrointestinal Symptom Rating Scale</title>
        <description>Measure Description: GSRS (Gastrointestinal Symptom Rating Scale) scores range 15-105 with higher scores indicating greater degree of symptoms&#xD;
GSRS:&#xD;
Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129-134. doi:10.1007/BF01535722</description>
        <time_frame>Screening (Day -7 to -14), Day 0, Day 3, Day 7, Day 14, Day 28</time_frame>
        <population>Subjects with biopsy proven celiac disease in remission were enrolled. On Day -14, one subject in the high gluten group missed completing the GSRS. On Day 0, two subjects (one in the low gluten group and one subject in the high gluten group) missed completing the GSRS. On Day 7, one subject in the high gluten group missed completing the GSRS. On Day 14, one subject in the high gluten group missed completing the GSRS. On Day 28, one subject in the high gluten group missed completing the GSRS.</population>
        <group_list>
          <group group_id="O1">
            <title>Day -14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O2">
            <title>Day -14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O3">
            <title>Day 0 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O4">
            <title>Day 0 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O5">
            <title>Day 3 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O6">
            <title>Day 3 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O7">
            <title>Day 7 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O8">
            <title>Day 7 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O9">
            <title>Day 14 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O10">
            <title>Day 14 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
          <group group_id="O11">
            <title>Day 28 Low Gluten Dose Group</title>
            <description>Subjects in the low gluten dose group consumed 3 grams of gluten per day.</description>
          </group>
          <group group_id="O12">
            <title>Day 28 High Gluten Dose Group</title>
            <description>Subjects in the high gluten dose group consumed 10 grams of gluten per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Response to Gluten Exposure Determined by Gastrointestinal Symptom Rating Scale</title>
          <description>Measure Description: GSRS (Gastrointestinal Symptom Rating Scale) scores range 15-105 with higher scores indicating greater degree of symptoms&#xD;
GSRS:&#xD;
Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129-134. doi:10.1007/BF01535722</description>
          <population>Subjects with biopsy proven celiac disease in remission were enrolled. On Day -14, one subject in the high gluten group missed completing the GSRS. On Day 0, two subjects (one in the low gluten group and one subject in the high gluten group) missed completing the GSRS. On Day 7, one subject in the high gluten group missed completing the GSRS. On Day 14, one subject in the high gluten group missed completing the GSRS. On Day 28, one subject in the high gluten group missed completing the GSRS.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.63" spread="7.05"/>
                    <measurement group_id="O2" value="19.20" spread="3.26"/>
                    <measurement group_id="O3" value="22.88" spread="9.58"/>
                    <measurement group_id="O4" value="18.40" spread="3.06"/>
                    <measurement group_id="O5" value="30.22" spread="11.63"/>
                    <measurement group_id="O6" value="26.45" spread="13.18"/>
                    <measurement group_id="O7" value="28.22" spread="9.87"/>
                    <measurement group_id="O8" value="27.30" spread="14.94"/>
                    <measurement group_id="O9" value="31.00" spread="13.71"/>
                    <measurement group_id="O10" value="31.00" spread="17.09"/>
                    <measurement group_id="O11" value="23.89" spread="11.59"/>
                    <measurement group_id="O12" value="19.40" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>P Value for the Gastrointestinal Symptom Rating Scale (GSRS) on Day 3 of the Gluten Challenge</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>P Value for Gastrointestinal Symptom Rating Scale (GSRS) from baseline to Day 14 of Gluten Challenge</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>P Value for Gastrointestinal Symptom Rating Scale (GSRS) between high gluten group and low gluten group across study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks after participant received first dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Gluten Group</title>
          <description>Subjects will eat 3g of gluten per day&#xD;
Gluten: 3g</description>
        </group>
        <group group_id="E2">
          <title>High Gluten Group</title>
          <description>Subjects will eat 10g of gluten per day&#xD;
Gluten: 10g</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <description>Participant developed heartburn and vomiting after drinking the lactulose/mannitol solution as part of the intestinal permeability test. Patient recovered without intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study did have few limitations. First, the study was only moderate in size and drawn from a single center. Many subjects had significant inflammation on duodenal biopsy at baseline which may have limited the effect of gluten challenge. Finally, the high and low gluten groups were significantly different in a few factors including time since diagnosis, time on a gluten-free diet and GSRS score.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ciaran Kelly</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-1272</phone>
      <email>ckelly2@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

